Emergence in protein derived nanomedicine as anticancer therapeutics: More than a tour de force

Publication date: Available online 18 January 2020Source: Seminars in Cancer BiologyAuthor(s): Zhenchang Wang, Kangkang Zhi, Zhongyang Ding, Yi Sun, Shuang Li, Manyuan Li, Kefeng Pu, Jun ZouAbstractCancer has thwarted as a major health problem affecting the global population. With an alarming increase in the patient population suffering from diverse varieties of cancers, the global demographic data predicts sharp escalation in the number of cancer patients. This can be expected to reach 420 million cases by 2025. Among the diverse types of cancers, the most frequently diagnosed cancers are the breast, colorectal, prostate and lung cancer. From years, conventional treatment approaches like surgery, chemotherapy and radiation therapy have been practiced. In the past few years, increasing research on molecular level diagnosis and treatment of cancers have significantly changed the realm of cancer treatment. Lately, uses of advanced chemotherapy and immunotherapy like treatments have gained significant progress in the cancer therapy, but these approaches have several limitations on their safety and toxicity. This has generated lot of momentum for the evolution of new drug delivery approaches for the effective delivery of anticancer therapeutics, which may improve the pharmacokinetic and pharmacodynamic effect of the drugs along with significant reduction in the side effects. In this regard, the protein-based nano-medicines have gained wider attention in the management of cancer. ...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research